Secukinumab for treating non-radiographic axial spondyloarthritis – Appraisal Consultation Document
In DRAFT guidance, NICE recommend secukinumab for active nonradiographic axial spondyloarthritis that has responded inadequately to non-steroidal anti-inflammatory drugs, only if it has also responded inadequately to anti-TNFs, or these are contraindicated or not suitable.
Source:
National Institute for Health and Care Excellence